{"id":"NCT01190189","sponsor":"GlaxoSmithKline","briefTitle":"Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study","officialTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-01","primaryCompletion":"2017-11-23","completion":"2017-11-23","firstPosted":"2010-08-27","resultsPosted":"2018-12-17","lastUpdate":"2019-06-19"},"enrollment":137,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"GSK580299 (Cervarix)","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"}],"summary":"This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV vaccine is not indicated for the subject's age group (26 years and older). This study is thus conducted to enable all women who received the control placebo in the primary NCT00294047 study to receive the GSK580299 vaccine.","primaryOutcome":{"measure":"Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs)","timeFrame":"During the entire study period (from Day 0 up to Month 12)","effectByArm":[{"arm":"Cervarix Group","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"26 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":28,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":137},"commonTop":["Anaemia","Ovarian cyst","Anxiety","Arthritis","Attention deficit/hyperactivity disorder"]}}